Literature DB >> 10884434

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

A Abi-Dargham1, J Rodenhiser, D Printz, Y Zea-Ponce, R Gil, L S Kegeles, R Weiss, T B Cooper, J J Mann, R L Van Heertum, J M Gorman, M Laruelle.   

Abstract

The classical dopamine hypothesis of schizophrenia postulates a hyperactivity of dopaminergic transmission at the D(2) receptor. We measured in vivo occupancy of striatal D(2) receptors by dopamine in 18 untreated patients with schizophrenia and 18 matched controls, by comparing D(2) receptor availability before and during pharmacologically induced acute dopamine depletion. Acute depletion of intrasynaptic dopamine resulted in a larger increase in D(2) receptor availability in patients with schizophrenia (19% +/- 11%) compared with control subjects (9% +/- 7%, P = 0.003). The increased occupancy of D(2) receptors by dopamine occurred both in first-episode neuroleptic-naive patients and in previously treated chronic patients experiencing an episode of illness exacerbation. In addition, elevated synaptic dopamine was predictive of good treatment response of positive symptoms to antipsychotic drugs. This finding provides direct evidence of increased stimulation of D(2) receptors by dopamine in schizophrenia, consistent with increased phasic activity of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884434      PMCID: PMC16677          DOI: 10.1073/pnas.97.14.8104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors.

Authors:  P Muller; P Seeman
Journal:  Life Sci       Date:  1977-12-15       Impact factor: 5.037

2.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

Review 3.  Increased dopamine transmission in schizophrenia: relationship to illness phases.

Authors:  M Laruelle; A Abi-Dargham; R Gil; L Kegeles; R Innis
Journal:  Biol Psychiatry       Date:  1999-07-01       Impact factor: 13.382

4.  Evolving behavior in the clinical and experimental amphetamine (model) psychosis.

Authors:  E H Ellinwood; A Sudilovsky; L M Nelson
Journal:  Am J Psychiatry       Date:  1973-10       Impact factor: 18.112

5.  Inhibitors of purified beef adrenal tyrosine hydroxylase.

Authors:  S Udenfriend; P Zaltzman-Nirenberg; T Nagatsu
Journal:  Biochem Pharmacol       Date:  1965-05       Impact factor: 5.858

6.  Synthesis of [123I]IBZM: a reliable procedure for routine clinical studies.

Authors:  Y Zea-Ponce; M Laruelle
Journal:  Nucl Med Biol       Date:  1999-08       Impact factor: 2.408

Review 7.  Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.

Authors:  M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2000-03       Impact factor: 6.200

8.  Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism.

Authors:  H K Brodie; D L Murphy; F K Goodwin; W E Bunney
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

9.  Metabolism of alpha-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis.

Authors:  K Engelman; E Jéquier; S Udenfriend; A Sjoerdsma
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

10.  Brain receptors for antipsychotic drugs and dopamine: direct binding assays.

Authors:  P Seeman; M Chau-Wong; J Tedesco; K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

View more
  317 in total

1.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 3.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

4.  Tuning pacemaker frequency of individual dopaminergic neurons by Kv4.3L and KChip3.1 transcription.

Authors:  B Liss; O Franz; S Sewing; R Bruns; H Neuhoff; J Roeper
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

Review 5.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

6.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 7.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

8.  [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].

Authors:  B Graf Schimmelmann; M Schacht; C Perro; M Lambert
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

9.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

10.  Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Adam L Halberstadt; Xiaoxi Zhuang; Jared W Young
Journal:  J Affect Disord       Date:  2013-11-16       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.